CEFOTAXIME SODIUM FOR INJECTION, BP 2 G
CEFOTAXIME SODIUM : 2 G · DIN 02434105 · STERIMAX INC
Health Canada status: MARKETED
What is CEFOTAXIME SODIUM FOR INJECTION, BP?
CEFOTAXIME SODIUM FOR INJECTION, BP 2 G contains CEFOTAXIME SODIUM : 2 G. It is listed in the Health Canada Drug Product Database under DIN 02434105, held by STERIMAX INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 12-Mar-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CEFOTAXIME SODIUM FOR INJECTION, BP used for?
Cefotaxime sodium for Injection, BP (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible strains of the designated micro-organisms including lower respiratory tract infections, urinary tract infections, bacteremia/septicemia, skin infections, intra-abdominal infections, gynecological infections, and central nervous system infections. It may also be used for prophylactic purposes in certain surgical procedures.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02434105 |
|---|---|
| Brand name | CEFOTAXIME SODIUM FOR INJECTION, BP |
| Generic / active ingredient | CEFOTAXIME SODIUM : 2 G |
| Manufacturer | STERIMAX INC |
| Strength | 2 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | J01DD01 CEFOTAXIME |
| AHFS class | 08:12.06.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Mar-2015 |
| Original market date | 2015-03-12 00:00:00 |
How is it stored and handled?
Cefotaxime sodium for Injection, BP in the dry state should be stored at room temperature (15-25°C), protected from light and heat. Reconstituted solution is chemically stable for 12 hours at room temperature (15-25°C) and for 24 hours under refrigeration (2-8°C).
How is it supplied?
500 mg, 1 g, 2 g vials
What can be used instead?
Other Canadian products sharing ATC code J01DD01 CEFOTAXIME. 2 of 21 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CEFOTAXIME SODIUM FOR INJECTION, BP | 1 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02434091 |
| CEFOTAXIME SODIUM FOR INJECTION BP | 0.5 G | POWDER FOR SOLUTION | AUROBINDO PHARMA LIMITED (UNIT VI) | APPROVED | DIN 02352168 |
| CEFOTAXIME SODIUM FOR INJECTION BP | 1 G | POWDER FOR SOLUTION | AUROBINDO PHARMA LIMITED (UNIT VI) | APPROVED | DIN 02352176 |
| CEFOTAXIME SODIUM FOR INJECTION BP | 2 G | POWDER FOR SOLUTION | AUROBINDO PHARMA LIMITED (UNIT VI) | APPROVED | DIN 02352184 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 1.0 G | POWDER FOR SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 02261510 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 2.0 G | POWDER FOR SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 02261529 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 250 MG | POWDER FOR SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED PRE MARKET | DIN 02261499 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 500 MG | POWDER FOR SOLUTION | STERIMAX INC | APPROVED | DIN 02434083 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 500 MG | POWDER FOR SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 02261502 |
| CLAFORAN - PWS INJ 1.0G/VIAL | 1 G | POWDER FOR SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 02225093 |
Who else supplies CEFOTAXIME worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFOTAXIME appears in 62 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.